SCHEMBL21883571

SCHEMBL21883571

CONC(=O)Nc1nccc(C)c1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 10/20 0.47
NPC1 O15118 9/20 0.47
SMN1; SMN2 Q16637 5/20 0.47
GFER P55789 1/20 0.46
ALDH1A1 P00352 2/20 0.44
HTT P42858 1/20 0.42
ATM Q13315 1/20 0.42
KDM4E B2RXH2 3/20 0.42
POLB P06746 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
NOS3 P29474 1/20 0.40
NOS2 P35228 1/20 0.40
TP53 P04637 1/20 0.38
HPGD P15428 1/20 0.37
SSTR2 P30874 1/20 0.37
MAPT P10636 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19779690 0.81 RAB9A (0.43) RAB9ANPC1SMN1; SMN2GFERALDH1A1
SCHEMBL22096817 0.81 RAB9A (0.43) RAB9ANPC1SMN1; SMN2GFERALDH1A1
SCHEMBL19781767 0.80 RAB9A (0.69) RAB9ANPC1SMN1; SMN2GFERALDH1A1
SCHEMBL11465233 0.79 LMNA (0.41) RAB9ANPC1SMN1; SMN2ALDH1A1HTT
SCHEMBL19780269 0.73 RAB9A (0.43) RAB9ANPC1SMN1; SMN2GFERALDH1A1
SCHEMBL25189926 0.71 GFER (0.43) RAB9ANPC1SMN1; SMN2GFERALDH1A1
SCHEMBL23491341 0.71 RAB9A (0.48) RAB9ANPC1SMN1; SMN2GFERALDH1A1
SCHEMBL6385162 0.70 NOS2 (0.52) RAB9ANPC1ALDH1A1KDM4EPOLB
SCHEMBL27681350 0.70 PTPN11 (0.39) RAB9ANPC1SMN1; SMN2ALDH1A1HTT
SCHEMBL22096821 0.70 RAB9A (0.47) RAB9ANPC1SMN1; SMN2GFERALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210171492-A1 SOMATOSTATIN MODULATORS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2021-06-10 US disclosed
US-10597377-B2 Somatostatin modulators and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2020-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10597377-B2 Somatostatin modulators and uses thereof SSTR5, SSTR2, SSTR4 RAB9A 2145/4885NPC1 1700/4885SMN1; SMN2 1197/4885
US-20210171492-A1 SOMATOSTATIN MODULATORS AND USES THEREOF SSTR5, SSTR2, SSTR4 RAB9A 2145/4885NPC1 1700/4885SMN1; SMN2 1197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.